The U.S. Food and Drug Administration has announced a new program that could dramatically shorten the time patients in lower-resource countries wait for access to innovative medicines. Called the Global Reliance Disclosure Program (GRDP), the initiative allows drug and biologic manufacturers to share the FDA's minimally redacted approval packages — including the agency's detailed scientific and regulatory assessments — directly with foreign regulatory authorities, according to an FDA press release published November 17, 2026.

The idea is straightforward: instead of a health authority in, say, sub-Saharan Africa or Southeast Asia conducting its own lengthy, resource-intensive review of a drug already deemed safe and effective by the FDA, it can rely on the U.S. agency's evaluation. The foreign authority retains full sovereignty over its final regulatory decision, but the process is meant to eliminate duplicative work and speed up patient access.

"The GRDP is a prime example of America First policies improving public health worldwide," said Grace Graham, FDA Deputy Commissioner for Policy, Legislation, and International Affairs, in the announcement. "The FDA is the global gold standard and making it easier for applicants to leverage our detailed scientific assessments to facilitate faster access for patients everywhere is an example of America's continued interest in advancing global health under the Trump Administration."

The program launched on October 30, 2026, with a President's Emergency Plan for AIDS Relief (PEPFAR) tentative approval for lenacapavir, a drug used for both HIV prevention and treatment. The FDA described this as "an especially meaningful starting point" given PEPFAR's mission to combat HIV/AIDS in vulnerable populations worldwide.

Currently, the GRDP is limited to PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug application products. But the FDA plans to expand the program significantly in January 2027 to cover all novel drug and biologics — specifically New Molecular Entity New Drug Applications and 351(a) Biologics License Applications. The agency also intends to launch a pathway in early 2027 to speed up requests for minimally redacted action packages for drugs and biologics already approved or licensed in the U.S., further accelerating global access to therapies already on the American market.

To participate, applicants must request inclusion within 10 calendar days of approval and confirm the package will be submitted to a foreign regulatory authority in support of a marketing application. The FDA says it will provide the minimally redacted package on an expedited basis. Requests for other purposes will not be processed under the GRDP and must go through the standard Freedom of Information Act (FOIA) process.

Mark Abdoo, FDA Associate Commissioner for Global Policy and Strategy, framed the program as a shift in how the agency exercises global leadership. "In an era of increasing global interdependence in pharmaceutical development and supply chains, the FDA's leadership is most effective when it is collaborative," he said. "The GRDP reflects a forward-looking vision of regulatory leadership: one defined not by exclusivity, but by the willingness to share expertise, elevate global standards, and put patients first — wherever they are."

The GRDP addresses what the FDA called "one of the most persistent and consequential challenges in global health": the gap between regulatory approval in high-capacity countries and patient access in lower-resource settings. Even after a drug is approved by the FDA, patients in many parts of the world may wait months or years for their own national health authority to complete an independent review, due to limited regulatory capacity and resources.

For university students — particularly those studying public health, global health policy, pharmacy, or medicine — the program represents a concrete example of how regulatory frameworks can be redesigned to address inequities in drug access. Students interested in careers in global health, pharmaceutical regulation, or health policy may find the GRDP a significant development to watch, as it could reshape how medicines reach populations in low- and middle-income countries.

The FDA also noted that beyond individual product approvals, the GRDP supports global health security by reducing the risk of fragmented or inconsistent product standards across markets, helping ensure that the same high-quality therapies reach patients regardless of where they live.